GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGY) » Definitions » Institutional Ownership

Lonza Group (Lonza Group) Institutional Ownership : 0.53% (As of Apr. 30, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Lonza Group Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lonza Group's institutional ownership is 0.53%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lonza Group's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lonza Group's Float Percentage Of Total Shares Outstanding is 0.00%.


Lonza Group Institutional Ownership Historical Data

The historical data trend for Lonza Group's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group Institutional Ownership Chart

Lonza Group Historical Data

The historical data trend for Lonza Group can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.08 0.08 0.08 0.08 0.07 0.04 0.04 0.49 0.53 0.53

Lonza Group Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Lonza Group (Lonza Group) Business Description

Address
Muenchensteinerstrasse 38, Basel, CHE, CH-4002
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.